<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02479581</url>
  </required_header>
  <id_info>
    <org_study_id>liman20150516</org_study_id>
    <nct_id>NCT02479581</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass</brief_title>
  <acronym>ERAS</acronym>
  <official_title>The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS) Applied on Cardiac Surgery With Cardiopulmonary Bypass: a Single Center, Randomized, Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the enhanced recovery after surgery (ERAS) concept over conventional
      postoperative care in patients with heart valve disease undergoing cardiac surgery with
      cardiopulmonary bypass. Half of participants will adherence to the ERAS, while the other half
      will under the conventional postoperative care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enhanced recovery after surgery (ERAS) or fast-track surgery is a perioperative and
      postoperative care concept initiated in the early 1990s aiming to reduce the length of
      hospital stays following elective abdominal surgery. The success of ERAS depends highly on
      multidisciplinary teamwork and patient compliance.

      This study intends to compare the Enhanced Recovery After Surgery (ERAS) concept applied to
      patients with heart valve disease undergoing cardiac surgery with cardiopulmonary bypass
      under traditional perioperative management of patients, committed to reducing patient's
      physical and psychological stress by surgical trauma, achieve the purpose of fast recovery,
      in order to establish an effective perioperative management during cardiopulmonary bypass
      surgery, improve patients' satisfaction and to accelerate postoperative rehabilitation
      safely.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The postoperative hospital time</measure>
    <time_frame>From pre-surgery to discharge, up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>From entering the ICU to roll out, up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The time of readiness to discharge</measure>
    <time_frame>From pre-surgery to discharge, up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The length of hospital stay</measure>
    <time_frame>From pre-surgery to discharge, up to 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalization cost</measure>
    <time_frame>When the patient is discharged</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perioperative major adverse events</measure>
    <time_frame>From pre-surgery to discharge, up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasoactive drugs Support Hours</measure>
    <time_frame>From the start of drugs to stop them, up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative tracheal tube time</measure>
    <time_frame>From the end of surgery to the removal of tracheal tube, up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation after surgery</measure>
    <time_frame>From the end of surgery to the recovery of spontaneous breathing, up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first bowel movement</measure>
    <time_frame>From the end of surgery to first exhaust, up to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative time to first exhaust</measure>
    <time_frame>From the end of surgery to first exhaust, up to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>baseline and 5 days after operation</time_frame>
    <description>1day before and 1-5days after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>baseline and 5 days after operation</time_frame>
    <description>1day before and 1-5days after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin</measure>
    <time_frame>baseline and 5 days after operation</time_frame>
    <description>1day before and 1-5days after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal B-type natriuretic peptide（NT-proBNP)</measure>
    <time_frame>baseline and 5 days after operation</time_frame>
    <description>1day before and 1-5days after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>baseline and 5 days after operation</time_frame>
    <description>1day before and 1-5days after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin I</measure>
    <time_frame>baseline and 5 days after operation</time_frame>
    <description>1day before and 1-5days after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Sedimentation Rate</measure>
    <time_frame>baseline and 5 days after operation</time_frame>
    <description>1day before and 1-5days after operation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Questions to the participants' health</measure>
    <time_frame>Six month</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">226</enrollment>
  <condition>Valvular Heart Disease</condition>
  <arm_group>
    <arm_group_label>ERAS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perioperative management follows the Enhanced Recovery after Surgery（ERAS） program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perioperative management follows the conventional program</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERAS group</intervention_name>
    <description>Intravenous infusion of flucloxacillin sodium 1g an hour before operation</description>
    <arm_group_label>ERAS group</arm_group_label>
    <other_name>&quot;yifen®&quot;,&quot;Flucloxacillin&quot;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERAS group</intervention_name>
    <description>No routine bowel preparation;
Normal eating 1 days before the operation;
No drinking 2h and solid food 6h before the operation;
Drink 10% glucose 250ml 3h before operation ;
Gastric mucosal protective agent was given 3 days before operation(Esomeprazole Magnesium Enteric-coated tablets 40mg/d);</description>
    <arm_group_label>ERAS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERAS group</intervention_name>
    <description>Emphasize the preoperative psychological preparation for patients.</description>
    <arm_group_label>ERAS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERAS group</intervention_name>
    <description>Received subcutaneous recombinant human erythropoietin (rhEPO)150（international unit/kg） once very two days from 2 days after hospital admission to 5 days postoperatively；</description>
    <arm_group_label>ERAS group</arm_group_label>
    <other_name>Recombinant Human Erythropoietin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERAS group</intervention_name>
    <description>No scopolamine and morphine before surgery; No midazolam; No anti - choline drugs;</description>
    <arm_group_label>ERAS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERAS group</intervention_name>
    <description>Solu-Medrol®:5mg/kg intravenous infusion during the surgery;</description>
    <arm_group_label>ERAS group</arm_group_label>
    <other_name>&quot;Methylprednisolone&quot;，&quot;Solu-Medrol® &quot;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERAS group</intervention_name>
    <description>Apply Transesophageal Echocardiography（TEE）after anesthesia induction;
Goal-directed fluid management.</description>
    <arm_group_label>ERAS group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERAS group</intervention_name>
    <description>Infusion of Human Albumin Grifol®20% 50ml;
Ultrafiltration(TERUMO CARDIOVASCULAR SYSTEMS (TERUMO®));
Shorten the Cardio-pulmonary Bypass line；
Continuous near infrared spectrum monitoring of cerebral oxygen saturation(MNIR-P100（chongqingmingxi®）)</description>
    <arm_group_label>ERAS group</arm_group_label>
    <other_name>Cardio-pulmonary Bypass measures, during the surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERAS group</intervention_name>
    <description>Monitor urine volume closely, over 0.5ml/kg·h.</description>
    <arm_group_label>ERAS group</arm_group_label>
    <other_name>Kidney protection measure during the surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERAS group</intervention_name>
    <description>Protective ventilation strategy：Low tidal volume about 6~8ml/kg and positive end expiratory pressure（PEEP） combined with lung recruitment maneuver</description>
    <arm_group_label>ERAS group</arm_group_label>
    <arm_group_label>Conventional control group</arm_group_label>
    <other_name>Lung protection measure during the surgery（Dräger Primus）</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERAS group</intervention_name>
    <description>Bilateral thoracic paravertebral block before induction of anesthesia;
Fast channel anesthesia:
Induction use Sufentanil 0.5~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2~0.6mg/kg; ②. Maintain use Remifentanil Hydrochloride for Injection 0.1~0.4ug/kg·min, Propofol Injection 2~6mg/kg·h, Sevoflurane 0.5~1.5（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg·h,Vecuronium 0.06~0.12mg/kg·h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over.</description>
    <arm_group_label>ERAS group</arm_group_label>
    <other_name>Anesthesia drugs during the surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERAS group</intervention_name>
    <description>Drink water after 6h, 200ml once, 2~3 times / day，
early ambulation，mobilization within 48 h,
Intravenous the conventional antiemetic drugs Tropisetron hydrochloride Injection 12mg qd；
Intravenous the lansoprazole 30mg q12h.</description>
    <arm_group_label>ERAS group</arm_group_label>
    <other_name>Gastrointestinal protection measures after the surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional control group</intervention_name>
    <description>Routine preoperative psychological preparation for patients.</description>
    <arm_group_label>Conventional control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERAS group</intervention_name>
    <description>After operation use Ropivacaine 100mg infiltrating intercostal wound and self-controlled intravenous analgesia pump is applicable(Sufentanil 0.05ug/kg·h combine with Ketamine 40ug/kg·h).</description>
    <arm_group_label>ERAS group</arm_group_label>
    <other_name>Analgesia drugs after the surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional control group</intervention_name>
    <description>Routine bowel preparation;
Liquid food eating 2 days before the operation;</description>
    <arm_group_label>Conventional control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional control group</intervention_name>
    <description>Intramuscular injection of scopolamine 0.3mg combined with morphine 10mg before surgery;</description>
    <arm_group_label>Conventional control group</arm_group_label>
    <other_name>scopolamine and morphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional control group</intervention_name>
    <description>Induction use Sufentanil 0.5~1ug/kg, Vecuronium 0.15mg/kg and Etomidate 0.2~0.6mg/kg,Midazolam0.05~0.1mg/kg ;
Maintain use Sufentanil 1~2ug/kg·h, Propofol 4~12mg/kg·h, Sevoflurane 1~3(minimal alveolar concentration)， Vecuronium 0.06~0.12mg/kg·h;</description>
    <arm_group_label>Conventional control group</arm_group_label>
    <other_name>Routine use of anesthesia medicine during the surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional control group</intervention_name>
    <description>Use self-controlled intravenous analgesia pump containing Sufentanil 0.07ug/kg·h</description>
    <arm_group_label>Conventional control group</arm_group_label>
    <other_name>Routine use of anesthesia medicine after the surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional control group</intervention_name>
    <description>Intravenous infusion of dexamethasone 20mg during the surgery</description>
    <arm_group_label>Conventional control group</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional control group</intervention_name>
    <description>Intravenous infusion of flucloxacillin sodium 1g before the operation</description>
    <arm_group_label>Conventional control group</arm_group_label>
    <other_name>&quot;yifen®&quot;,&quot;Flucloxacillin&quot;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart function grade II - III (Using the cardiac function classification method
             formulated by American Heart Disease Institute)

          -  The in - hospital was treated with extracorporeal circulation operation and general
             anesthesia.

          -  Had a good cognition, and signed the informed consent.

          -  Aged between 18 and 70.

          -  The age, clinical examination and other generally situation of the two groups of
             patients had no statistical significance.

        Exclusion Criteria:

          -  Combined with other blood coagulation dysfunction, serious brain, liver and kidney
             dysfunction, endocrine system diseases and serious infectious disease.

          -  Patients with severe mental disorders cannot cooperate with the treatment.

          -  Emergency operation

          -  Have taboo of Echocardiography and pulmonary catheterization by echocardiography.

          -  Patients have been fitted with a pacemaker.

          -  Allergic to erythropoietin.

          -  Suspected or had alcohol, drug abuse history.

          -  Spinal deformity or paravertebral lesions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>e wang, phD</last_name>
    <role>Study Director</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410078</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Bakker N, Cakir H, Doodeman HJ, Houdijk AP. Eight years of experience with Enhanced Recovery After Surgery in patients with colon cancer: Impact of measures to improve adherence. Surgery. 2015 Jun;157(6):1130-6. doi: 10.1016/j.surg.2015.01.016. Epub 2015 Mar 16.</citation>
    <PMID>25791027</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoffmann H, Kettelhack C. Fast-track surgery--conditions and challenges in postsurgical treatment: a review of elements of translational research in enhanced recovery after surgery. Eur Surg Res. 2012;49(1):24-34. doi: 10.1159/000339859. Epub 2012 Jul 11. Review.</citation>
    <PMID>22797672</PMID>
  </results_reference>
  <results_reference>
    <citation>Kehlet H, Dahl JB. Anaesthesia, surgery, and challenges in postoperative recovery. Lancet. 2003 Dec 6;362(9399):1921-8. Review.</citation>
    <PMID>14667752</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2015</study_first_submitted>
  <study_first_submitted_qc>June 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2015</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enhanced Recovery after Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Floxacillin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 1, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>August 31, 2017</submitted>
    <returned>April 12, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

